Fecal DNA Testing for Colorectal cancer Screening

用于结肠直肠癌筛查的粪便 DNA 检测

• 批准号: 8713417
• 负责人: BAOCHUAN GUO
• 金额: $ 22.5万
• 依托单位: GLC BIOTECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-01 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8713417
• 关键词: Advisory Committees; American; Biological Assay; Blood Tests; Clinical; DNA; DNA Markers; DNA analysis; Detection; Development; Early Diagnosis; Excision; Fecal occult blood; Feces; Fusobacterium nucleatum; Healthcare; Mails; Malignant Neoplasms; Methods; Molecular; Office Visits; Patients; Performance; Phase; Physicians; Preparation; Procedures; Recruitment Activity; Sample Size; Sampling; Screening for cancer; Sensitivity and Specificity; Small Business Innovation Research Grant; Societies; Specificity; Specimen; Survival Rate; Testing; Training; Validation; Weight; adenoma; base; colorectal cancer screening; compliance behavior; cost; cost effective; design; improved; innovation; news; novel marker; public health relevance; research clinical testing; screening; success; validation studies

DESCRIPTION (provided by applicant): This is the Phase I application of a SBIR project that will be devoted to develop a new fecal DNA test for CRC screening, which will utilize a new tri-marker panel discovered in our preliminary study. CRC is the second deadliest cancer in USA. The good news is that early detection along with resection is associated with a five-year survival rate of nearly 100%. Fecal DNA testing is emerging as one of the most promising methods to replace fecal occult blood tests for CRC screening. Recently, we discovered a new panel of stool DNA markers that could detect 86% of CRC with a specificity of 82%. Because this new panel contains no methylated DNA markers, a great benefit of using it for CRC screening is that the quantity of the stool used to extract DNA could be reduced by at least 10 fold, greatly reducing the complexity and cost of fecal DNA testing. To the best of our knowledge, this may be the simplest panel of markers that can achieve such high detection sensitivity with good specificity. The specific aim of this Phase I project is to validate this new marker panel for CRC screening. The validation will be carried out using the training-test set procedure. The milestone set for Phase I is to demonstrate that the new marker panel can detect ~85% of CRC with a specificity of ~80%.

描述（由申请人提供）：这是SBIR项目的I期申请，该项目将致力于开发用于CRC筛查的新粪便DNA检测，该检测将利用我们初步研究中发现的新三标记物组。CRC是美国第二大致命癌症。好消息是，早期发现沿着切除与近100%的五年生存率相关。粪便DNA检测正在成为最有前途的方法之一，以取代粪便潜血试验的CRC筛查。最近，我们发现了一组新的粪便DNA标记物，可以检测86%的CRC，特异性为82%。由于这种新的面板不含甲基化DNA标记物，使用它进行CRC筛查的一个很大的好处是，用于提取DNA的粪便数量可以减少至少10倍，大大降低了粪便DNA检测的复杂性和成本。据我们所知，这可能是最简单的一组标志物，可以实现如此高的检测灵敏度和良好的特异性。该I期项目的具体目标是验证这种用于CRC筛查的新标志物组。将使用训练测试集程序进行确认。第一阶段的里程碑是证明新的标志物组可以检测到约85%的CRC，特异性约为80%。